Misplaced Pages

Foretinib

Names
Preferred IUPAC name N-quinolin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Other names XL880; EXEL-2880; GSK1363089; GSK089
Identifiers
CAS Number	849217-64-7
3D model (JSmol)	Interactive image
ChEBI	CHEBI:91418
ChEMBL	ChEMBL1908393
ChemSpider	24608641
DrugBank	DB12307
ECHA InfoCard	100.158.129
KEGG	D09618
PubChem CID	42642645
UNII	81FH7VK1C4
CompTox Dashboard (EPA)	DTXSID20918193
InChI Key: CXQHYVUVSFXTMY-UHFFFAOYSA-N InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
SMILES COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
Properties
Chemical formula	C34H34F2N4O6
Molar mass	632.665 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references

Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of October 2015 it appears development has been discontinued.

Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).

See also

• c-Met inhibitors
• Cabozantinib, a similar molecule and kinase inhibitor with FDA approval
• VEGFR inhibitor
• tyrosine-kinase inhibitor

References

1. Hedgethorne, K.; Huang, P.H. (2010). "Foretinib. c-Met and VEGFR-2 inhibitor, Oncolytic". Drugs of the Future. 35 (11): 893–901. doi:10.1358/dof.2010.35.11.1529012.
2. "XL880 (GSK1363089)". Exelixis, Inc.
3. "Foretinib". clinicaltrials.gov.
4. "Foretinib - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018.
5. Qian, F; Engst, S; Yamaguchi, K; Yu, P; Won, KA; Mock, L; Lou, T; Tan, J; et al. (2009). "Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases". Cancer Research. 69 (20): 8009–16. doi:10.1158/0008-5472.CAN-08-4889. PMID 19808973.

• Tyrosine kinase inhibitors
• Quinolines
• 4-Morpholinyl compounds
• Cyclopropanes
• 4-Fluorophenyl compounds
• Abandoned drugs